Anteris Technologies completes crucial final animal study ahead of heart valve replacement clinical trial
Formal results from a three-month study of Anteris’ DurAVR™ heart valve replacement in six sheep will be available in the next month.
Company
Anteris Technologies Pty Ltd
ASX:AVR
Anteris Technologies Pty Ltd is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
137 stories · page 2 of 2
Anteris Technologies appoints highly experienced chief medical officer
The appointment of Dr Meduri, a recognised leader in the field of valvular heart disease, is expected to give further credibility to Anteris’ DurAVR™ aortic replacement valve.
Anteris Technologies extends manufacturing agreement with LeMaitre for CardioCel™ and VascuCel™
Anteris Technologies is a structural heart company delivering clinically superior and durable solutions through better science and better design.
Anteris Technologies raises $9 million by issuing placement shares to sophisticated investors
CEO Paterson said: “With this new capital round we will continue to deliver on our plan of achieving EFS approval in 2021 as well as advancing our Coronary Artery Bypass Graft and surgical valve projects.”
Anteris Technologies halted with capital raising announcement upcoming
Securities will remain halted until Monday, August 2, 2021, or when an announcement is released to the market.
Anteris Technologies granted a patent for ‘Sterilized packaging system for catheter’ invention
Having a specialised, proprietary sterilization system enhances the intellectual property barrier around Anteris’ key technologies.
Anteris Technologies has 3D single-piece Transcatheter Heart Valve DurAVR™ featured during TVT 2021
CEO Wayne Paterson said: “Having DurAVR™ recognized at this very important meeting is a clear demonstration of support for our potential within the Structural Heart Faculty.”
Anteris Technologies achieves breakthrough in ADAPT® products to create consistently thin tissue
The proven benefits of its ADAPT® tissue technology, paired with DurAVR™’s unique 3D single piece aortic valve design, have potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challen
Anteris Technologies selected to showcase transcatheter heart valve at TVT 2021 ‘Call For Innovation’
“As we continue to advance our program and gain prestigious recognition such as being accepted for this presentation, we are increasingly confident that DurAVR™ will be a major market entrant into the global TAVR market,” says CEO.
Anteris Technologies' ADAPT® conduit proof of concept animal study finds no calcification in carotid artery
Results from the study validate ADAPT® ’s anti-calcification properties in highly problematic areas of surgery and move the company closer to a viable alternative for patients of coronary by-pass surgery.
Anteris Technologies director supports biotech strategy with on market purchase
The company is focused on investing in, researching and developing its ADAPT® technology and product development pipeline including DurAVR™, its 3D single-piece aortic valve.
Anteris Technologies boosts funds with $1.49 million R&D refund
It will repay the short-term facility entered into with Mitchell Asset Management for the advance of $1.22 million for its forecasted R&D tax incentive.
Anteris Technologies’ $2.3 million placement strongly supported by Top 10 institutional shareholders
The capital raising validates the structural heart company’s next-generation technologies including The Anteris DurAVR™ aortic replacement valve and ADAPT® tissue technology.
Anteris Technologies hits key milestone on path to FDA submission for ComASUR™ Transfemoral Delivery System
A series of animal studies have been completed to demonstrate the feasibility of the DurAVR™ THV (prosthetic aortic valve) and its bespoke ComASUR™ delivery system.
Anteris Technologies achieves “another standout year” as it progresses towards becoming market leader in combating aortic stenosis
Anteris’ DurAVR™ prosthetic valve has the potential to solve the problems associated with current aortic valve replacement options, offering a functional valve for life in an estimated US$10 billion market by 2025.
Anteris Technologies arranges expanded $3.05 million Mercer funding package and closes second tranche of facility for $1 million
The funding provides additional working capital as Anteris advances the development of DurAVR™, its 3D single-piece aortic valve for the treatment of aortic stenosis.
Anteris Technologies' study results indicate ADAPT® treated tissue has superior anti-calcification attributes
Results correlated with existing clinical data and those of the prior head-to-head study with a similar protocol which produced significant differentials between ADAPT® tissue and Edwards Life Sciences’ Thermafix™ tissue.
Anteris Technologies gets speeding ticket from ASX after sustained share price gains
The ‘structural heart’ biotech has gained 182% since the start of the year, following a big investment in the development of its flagship product, DurAVR™.
Anteris Technologies closes first $2.5 million tranche under convertible security and share purchase agreement with Mercer
The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.
Anteris Technologies unveils $20 million funding package to develop DurAVR™, its 3D single-piece aortic valve for aortic stenosis
New York-based investment fund, Mercer Street Global Opportunity Fund LLC will provide a $16.5 million discretionary drawdown facility
Anteris Technologies receives advance for $1.22 million research and development tax incentive
The R&D refund confirms the company’s ongoing commitment to invest in, research and develop its technology and product development pipeline.
Anteris Technologies raises $1.1 million to advance 3D aortic valve development
Anteris’ 3D single-piece aortic valve, DurAVR™, was selected as a “Best Innovation” at the PCR London Valves 2020 virtual conference, with data from the company’s first-in-human trial presented.
Anteris Technologies in trading halt with capital raising news pending
The company’s three-dimensional single-piece aortic valve DurAVR™ was selected as a 'Best Innovation' at last month’s PCR London Valves 2020 virtual conference.
Anteris Technologies progresses towards completing DurAVR™ Transcatheter Heart Valve study
Proven benefits of the ADAPT® tissue technology, paired with the unique 3D single piece aortic valve design of DurAVR™, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to challen
Anteris Technologies’ 3D single-piece aortic valve DurAVR™ a ‘Best Innovation’ at PCR London Valves 2020
Data from its first-in-human trial will be presented at the conference to be held on November 22-24, 2020, virtually, given the COVID-19 restrictions.
Anteris Technologies to present at Credit Suisse Structural Heart Sessions next week
The company is focused on developing next-generation technologies that help healthcare professionals create life-changing outcomes for patients.
Anteris Technologies comparison study shows ADAPT® treated tissue has superior anti-calcification attributes
Proven benefits of the ADAPT® tissue technology, paired with the unique 3D single piece aortic valve design of DurAVR™, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to challen
Anteris Technologies exceeds expectations as DurAVR™ patient outcomes demonstrate superiority over existing valves
Early results show that the DurAVR™ valve was easy to manipulate and able to be optimally positioned by the implanting surgeon in the aortic valve replacement procedures.
Anteris Technologies appoints Professor Bernard Prendergast to TAVR Medical Advisory Board
Business restrictions caused by COVID-19 precludes face-face meetings but this has not dampened interest in Anteris’ unique technology.
Anteris Technologies' operations advancing as scheduled; highly positive on DurAVR™ valve capabilities
If these results continue, DurAVR™ will be the first TAVR valve to deliver a truly functional cure for severe aortic stenosis patients.
Anteris Technologies outlines new data showing DurAVR™ valve capabilities
The company presented the data at the TAVR Key Opinion Leader Symposium held on July 20.
Anteris Technologies hosting key opinion leader symposium to update on TAVR R&D program and ADAPT trial
The structural heart company will update on its TAVR R&D program and the ongoing first-in-human trial of its ADAPT® 3D single-piece aortic valve for Surgical Aortic Valve Replacement procedures.
Anteris Technologies sets sights on biotech operational milestones
The company is focused on reaching its operational goals for 2020 including completing a study of its proprietary DurAVR™ Transcatheter Heart Valve by year-end.
Anteris Technologies focused on commercialising DurAVR™ 3D single piece aortic valve
The company’s DurAVR™ product is a highly durable 3D single-piece aortic valve for the treatment of aortic stenosis.
Anteris Technologies receives $734,899 R&D tax incentive refund
The company has received a tax incentive for R&D costs incurred in developing its ADAPT® technology and products including the DurAVR™ 3D single-piece Aortic Valve.
Anteris Technologies begins early transcatheter aortic valve replacement animal study
The study will allow the company to make refinements to the DurAVR™ aortic valve, which will be applied to the device used in the planned US FDA submission for a human clinical trial in 2021.
Anteris Technologies changes name from Admedus Ltd following shareholder approval
Anteris is a structural heart company with technology, ADAPT® and DurAVR™, that solves critical issues with marketed heart valves.